From - A Hematology Oncology Wiki
Jump to: navigation, search - A Free Hematology/Oncology Reference

Regimens: 3,248 Regimen variants: 4,920
Solid Tumors Malignant Hematology Cross-Disciplinary Classical Hematology
Mobile Version Editorial Board Desktop Version
Disease index Intervention index Regimen index General reference
If this is your first time visiting, please go to the tutorial page or just start exploring!

Links to all main disease pages

Solid Tumors
Breast Oncology
Breast cancer Breast cancer, ER/PR-positive Breast cancer, HER2-positive Breast cancer, triple negative (TNBC)
Breast cancer, BRCA-mutated Breast cancer, PIK3CA-mutated
Dermatologic Oncology
Cutaneous BCC Cutaneous SCC Melanoma Melanoma, BRAF-mutated
Melanoma, NRAS-mutated Merkel cell carcinoma Uveal melanoma
Endocrine Oncology
Adrenocortical carcinoma Neuroendocrine tumor Pancreatic NET Pheochromocytoma
Thyroid cancer Thyroid cancer, BRAF-mutated
Gastrointestinal Oncology
Anal cancer Cholangiocarcinoma Colon cancer Colon cancer, KRAS wild-type
Esophageal cancer Gallbladder cancer Gastric cancer Gastrointestinal stromal tumor (GIST)
Hepatocellular carcinoma Periampullary adenocarcinoma Pancreatic cancer Pancreatic NET
Rectal cancer
Genitourinary Oncology
Bladder cancer Penile cancer Prostate cancer Renal cell carcinoma (RCC)
Testicular cancer
Gynecologic Oncology
Cervical cancer Endometrial cancer Gestational trophoblastic neoplasia Ovarian cancer
Vulvar cancer
Head & Neck Oncology
Head and neck cancer Nasopharyngeal carcinoma HPV+ Oropharyngeal cancer Thyroid cancer
Thyroid cancer, BRAF-mutated
Anaplastic glioma Glioblastoma Low-grade glioma Meningioma
CNS carcinoma CNS leukemia CNS lymphoma CNS melanoma
Bone sarcoma Ewing sarcoma Gastrointestinal stromal tumor (GIST) Osteosarcoma
Rhabdomyosarcoma Soft tissue sarcoma (STS) Vascular sarcoma
Thoracic Oncology
Esophageal cancer Lung cancer, non-small cell (NSCLC) NSCLC, ALK-positive NSCLC, BRAF-mutated
NSCLC, EGFR-mutated NSCLC, ROS1-positive Lung cancer, small cell (SCLC) Mesothelioma
MSI-H or dMMR SMO or PTCH-1 (Hedgehog) Adenocarcinoma of unknown primary NET of unknown primary
SCC of unknown primary

back to top
Malignant Hematology
Acute leukemias
Acute myeloid leukemia (AML) AML, FLT3-positive AML, IDH-mutated Acute promyelocytic leukemia (APL)
B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL) Blastic plasmacytoid dendritic cell neoplasm
CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myelogenous leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome Primary & secondary myelofibrosis Polycythemia vera (PV) Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma CNS lymphoma Diffuse large B-cell lymphoma (DLBCL) HIV-associated lymphoma
Hodgkin lymphoma (HL) Mantle cell lymphoma (MCL) Mediastinal gray-zone lymphoma (MGZL) Primary mediastinal B-cell lymphoma (PMBL)
Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL) Follicular lymphoma (FL) Hairy cell leukemia (HCL) Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
Marginal zone lymphoma (MZL) Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis Multiple myeloma (main page) MM, induction MM, consolidation & maintenance
MM, relapsed/refractory Plasma cell leukemia POEMS syndrome
T-cell and NK-cell neoplasms
Adult T-cell leukemia/lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Cutaneous T-cell lymphoma (CTCL) Extranodal NK/T-cell lymphoma, nasal type
Large granular lymphocytic (LGL) leukemia NK/T-cell lymphoma Peripheral T-cell Lymphoma (PTCL) T-cell acute lymphoblastic lymphoma (T-LBL)
T-cell prolymphocytic lymphoma (T-PLL)
Lymphoproliferative disorders
Castleman disease Post-transplant lymphoproliferative disorder (PTLD)
Histiocyte disorders
Erdheim-Chester disease Hemophagocytic lymphohistiocytosis (HLH) Langerhans cell histiocytosis Rosai-Dorfman-Destombes disease

back to top
Pediatric Oncology
B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ Ewing sarcoma Hepatoblastoma
Medulloblastoma Neuroblastoma Osteosarcoma T-cell acute lymphoblastic leukemia (T-ALL)
Wilms tumor
Stem cell mobilization Allogeneic HSCT Autologous HSCT Graft versus host disease (GVHD)

back to top
Classical Hematology
Hemostasis and thrombosis
Acquired coagulopathy Antiphospholipid antibody syndrome Heparin-induced thrombocytopenia (HIT) Hereditary hemorrhagic telangiectasia (HHT)
Inherited coagulopathy Inherited thrombophilia Venous thromboembolism (VTE)
Aplastic anemia Autoimmune cytopenia Immune thrombocytopenia (ITP) Thrombocytopenia in liver disease
WHIM syndrome
Hemolytic disorders
Atypical hemolytic uremic syndrome (aHUS) Autoimmune hemolytic anemia (AIHA) Cold agglutinin disease Paroxysmal nocturnal hemoglobinuria (PNH)
Sickle cell anemia Thrombotic thrombocytopenic purpura (TTP)
Browse our complete index of pages

Additional Information

Created as a knowledge base for hematology & oncology providers, is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.

Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.

Priorities of this project include:

Additional possibilities for this project may include:

  • Creating synopses of pivotal clinical trials and regimens
  • Prioritizing regimens by their efficacy and/or toxicity
  • Capturing historical regimens that were standard-of-care prior to 2005
  • Checklists for common clinical scenarios/diseases
  • Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.